The number of bird flu cases in Central Massachusetts is relatively low, compared to a swath of the state that runs from ...

Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance ...

Evercore ISI lowered the firm’s price target on Moderna (MRNA) to $50 from $60 and keeps an In Line rating on the shares. The firm is updating ...

As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

Shares of Moderna Inc. climbed nearly 1% on Friday, reaching levels last seen on Jan. 10, as retail sentiment turned ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...

Netflix earnings after the bell drive focus in tech stocks. Dow and S&P climb as optimism over trade policy fuels market ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The biotech, renowned for its pioneering development of vaccines based on ...

Moderna was awarded an additional US$590 million ($807.18 million) from the US government to help the company develop a vaccine aimed at protecting people from bird flu. The funding will support ...

US health officials announced Friday they were awarding $590 million to Moderna to develop mRNA vaccines against influenza, including advancing the company's bird flu vaccine, as fears of a new ...

Moderna's influenza vaccine candidate uses conventional mRNA technology that was leveraged successfully during the COVID-19 response, resulting in one of the first two FDA-authorized - and ...